-
Nov 6, 2024 | 
myastheniagravisnews.com | Andrea Lobo |Patricia Inacio |Margarida Maia |Patricia Valerio
Myasthenia gravis (MG) patients who are women or have a tumor in the thymus gland are more likely to require intensive care due to disease exacerbation, a retrospective study in Finland suggests. Patients with late-onset disease in whom disease symptoms become apparent after the age of 50 were also more likely to need intensive care, the study found. “Special attention to early treatment choices should therefore be given, especially in [late-onset MG] patients,” the researchers wrote.
-
Jun 3, 2024 | 
lupusnewstoday.com | Margarida Maia |Candace J. Semien |Lindsey Shapiro |Patricia Valerio
GRI Bio announced what it called “encouraging preclinical data” on two systemic lupus erythematosus (SLE) treatment candidates. SLE is the most common form of lupus. GRI-0124, an oral small molecule being developed to activate natural killer T-cells, or NKT cells, and keep autoimmune attacks in check eased inflammation and prolonged survival in a mouse model of SLE, the company said.
-
May 8, 2024 | 
cushingsdiseasenews.com | Patricia Inacio |Andrea Lobo |Lindsey Shapiro |Patricia Valerio
A technique called trabecular bone score, or TBS, may be better at assessing bone damage and loss than bone mineral density, the current gold standard, in successfully treated patients with Cushing’s disease, according to a recent study. High cortisol levels characterize Cushing’s, and they are known to increase the risk of fractures due to bone loss, particularly in the lumbar spine, its researchers noted.
-
Apr 23, 2024 | 
alsnewstoday.com | Margarida Maia |Lindsey Shapiro |Steve Bryson |Patricia Valerio
Treatment with NurOwn (debamestrocel), which BrainStorm Cell Therapeutics is developing for amyotrophic lateral sclerosis (ALS), may bring about changes in biomarkers of inflammation and neurodegeneration that predict clinical outcomes. The findings come from the Phase 3 trial (NCT03280056) that tested NurOwn against a placebo in 189 adults with rapidly progressing ALS. The trial failed to meet its main goal of slowing disease progression, but showed promise in those with less advanced disease.
-
Apr 8, 2024 | 
angioedemanews.com | Patricia Inacio |Danita Jones |Mary M. Chapman |Patricia Valerio
The use of vaccines against SARS-CoV-2, the virus that causes COVID-19, was not linked to an increased risk of disease worsening in people with hereditary angioedema (HAE), according to a small, single-center study from Turkey. The study also found that the viral infection was not always associated with disease worsening or activation.
-
Mar 25, 2024 | 
lupusnewstoday.com | Andrea Lobo |Patricia Valerio |Lindsey Shapiro |Kellie McRae
Three women with the autoimmune conditions systemic lupus erythematosus (SLE) and Sjögren’s syndrome saw their symptoms ease after starting a diet rich in plant-based raw foods, according to a recent case series report. The diet included mainly leafy greens, cruciferous vegetables, flax or chia seeds as a source of omega-3 polyunsaturated fatty acids, and water.
-
Mar 22, 2024 | 
pulmonaryfibrosisnews.com | Marisa Wexler |Charlene Marshall |Mary Chapman |Patricia Valerio
Almee, a behavioral therapy app designed to help ease anxiety in people with pulmonary fibrosis (PF), has been granted breakthrough device designation by the U.S. Food and Drug Administration (FDA). The FDA gives this designation to medical devices that have the potential to provide a more effective treatment or diagnosis of serious and life-threatening conditions.
-
Jan 8, 2024 | 
parkinsonsnewstoday.com | Andrea Lobo |Patricia Inacio |Margarida Maia |Patricia Valerio
Monitoring symptoms at home using smartwatch-smartphone technology collected individual profiles of tremor and activity fluctuations among people with advanced Parkinson’s disease being treated with levodopa. The technology can provide useful information to improve treatments and patient outcomes and, by combining it with telemedicine and other digital health tools, could help reduce healthcare costs and the need for medical resources.
-
Jan 5, 2024 | 
pulmonaryfibrosisnews.com | Mary Chapman |Charlene Marshall |Margarida Maia |Patricia Valerio
Almee, an investigational app that offers personalized treatment to help people with pulmonary fibrosis (PF), was found to significantly reduce anxiety levels in PF patients who participated in a pivotal randomized study. Positive results from the COMPANION (NCT05330312) study were announced by Alex Therapeutics and Vicore Pharma, which are jointly developing the app, a digital cognitive behavioral therapy (CBT) intervention that can be accessed through a smartphone or tablet.
-
Jan 3, 2024 | 
science.org | Chanho Shin |Brian Imbiakha |Vlastimil Novak |Patricia Valerio
Research Article NEUROSCIENCE Patricia Valerio https://orcid.org/0000-0002-9750-3813, Julien Rechenmann, [...] , Suyash Joshi https://orcid.org/0000-0003-2397-4847, Gioia De Franceschi https://orcid.org/0000-0001-6429-3402, and Tania Rinaldi Barkat https://orcid.org/0000-0001-8650-0986 [email protected]+2 authors fewerAuthors Info & Affiliations Abstract Stimulus-specific adaptation (SSA), the reduction of neural activity to a common stimulus that does not generalize to other, rare...
